2016年4月12日,美国食品和药物管理局（FDA）已批准Venclexta单药治疗携带17p删除突变（del 17p）以及之前已接受至少一种疗法的慢性淋巴细胞白血病（CLL）患者。Venclexta是一种每日一次的口服药物，适用于采用FDA批准的一款伴随诊断试剂盒Vysis CLL FISH探针试剂盒（雅培生产）确认为存在17p删除突变的CLL患者。 Venclexta是FDA批准的首个B细胞淋巴瘤因子-2（BCL-2）抑制剂，之前FDA已授予其突破性药物认定、优先审查资格、加速审批资格。值得一提的是，截至目前，Venclexta已斩获FDA 3个突破性药物资格。BCL-2蛋白支持癌细胞的生长，并且在许多CLL患者中过度表达，代表着血液癌症治疗的一个新靶标。Venclexta能够帮助恢复让白血病细胞自我毁灭的自然过程，代表着预后极差且治疗选择十分有限的17p删除突变CLL患者群体中的一种新的治疗方式。 根据美国国家癌症研究所（NCI），慢性淋巴细胞白血病（CLL）是成人中最常见的白血病类型，每年新确诊15000例。染色体异常删除突变del 17p与癌症的恶化和耐药性相关，del 17p是指17号染色体部分片段丢失，携带该突变的患者被认为预后最差。据估计，17p删除突变发生在大约10%的初治（未经治疗）CLL患者以及大约20%的复发性CLL患者，使得疾病难以治疗，患者通常平均寿命不到3年。 Venclexta的获批，是基于一项II期临床研究（M13-982）的积极数据。该研究是一项开放标签、单组、多中心II期研究，在携带17p删除突变（del 17p）的复发性或难治性慢性淋巴细胞白血病（CLL）患者中开展。数据显示，venetoclax单药治疗使患者癌细胞数量实现临床意义的降低，总缓解率（ORR）高达79.4%，达到了研究的主要终点。此外，有7.5%的患者实现伴有或不伴有骨髓完全恢复（无正常血细胞完全缓解）的完全缓解（CR/CRi）。该研究还对45例患者进行了血液微小残留病（MRD）评估，其中18例实现MRD阴性，意味着在血液中未检测到癌细胞；这18例患者中有10例还进行了骨髓评估，其中6例为MRD阴性。 在研究的一年时，84.7%的所有缓解、94.4%的MRD阴性缓解能够维持。一年无进展生存率和总生存率分别为72%和86.7%。研究中，未观察到与venetoclax相关的意外安全信号。最常见的3/4级不良事件包括白细胞计数低（40%）、红细胞计数低（18%），血细胞计数低（15%）。3级或以上感染发生于20%的患者，实验室肿瘤溶解综合征5例，无临床后果。 关于Venetoclax： venetoclax是一种口服的B细胞淋巴瘤因子-2（BCL-2）抑制剂，BCL-2在细胞凋亡（程序性细胞死亡）中发挥重要作用，可阻止一些细胞（包括淋巴细胞）的凋亡，并且在某些类型癌症中过度表达，与耐药性的形成相关。venetoclax旨在选择性抑制BCL-2的功能，恢复细胞的通讯系统，让癌细胞自我毁灭，达到治疗肿瘤的目的。 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA. VENCLEXTA TM (venetoclax) tablets, for oral use Initial U.S. Approval: 2016 INDICATIONS AND USAGE VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (1) DOSAGE AND ADMINISTRATION Initiate therapy with VENCLEXTA at 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg. (2.2) VENCLEXTA tablets should be taken orally once daily with a meal and water. Do not chew, crush, or break tablets. (2.2) Perform prophylaxis for tumor lysis syndrome. (2.3) DOSAGE FORMS AND STRENGTHS Tablets: 10 mg, 50 mg, 100 mg (3) CONTRAINDICATIONS Concomitant use of VENCLEXTA with strong inhibitors of CYP3A at initiation and during ramp-up phase is contraindicated. (2.5, 4, 7.1) WARNINGS AND PRECAUTIONS Tumor Lysis Syndrome (TLS): Anticipate TLS; assess risk in all patients. Premedicate with anti-hyperuricemics and ensure adequate hydration. Employ more intensive measures (intravenous hydration, frequent monitoring, hospitalization) as overall risk increases. (2.3, 5.1) Neutropenia: Monitor blood counts and for signs of infection; manage as medically appropriate. (2.4, 5.2) Immunization: Do not administer live attenuated vaccines prior to, during, or after VENCLEXTA treatment. (5.3) Embryo-Fetal Toxicity: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment. (5.4) ADVERSE REACTIONS The most common adverse reactions (≥20%) were neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Avoid concomitant use of VENCLEXTA with moderate CYP3A inhibitors, strong or moderate CYP3A inducers, P-gp inhibitors, or narrow therapeutic index P-gp substrates. (2.5, 7.1, 7.2) If a moderate CYP3A inhibitor or a P-gp inhibitor must be used, reduce the VENCLEXTA dose by at least 50%. (2.5, 7.1) If a strong CYP3A inhibitor must be used after the ramp-up phase, reduce the VENCLEXTA dose by at least 75%. (2.5, 7.1) If a narrow therapeutic index P-gp substrate must be used, it should be taken at least 6 hours before VENCLEXTA. (7.2) USE IN SPECIFIC POPULATIONS Lactation: Discontinue breastfeeding. (8.2) See17for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 4/2016 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection Select patients for the treatment of relapsed or refractory CLL with VENCLEXTA based on the presence of 17p deletions in blood specimens [see Indications and Usage (1) and Clinical Studies (14)]. Patients without 17p deletion at diagnosis should be retested at relapse because acquisition of 17p deletion can occur. Information on FDA-approved tests for the detection of 17p deletions in CLL is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage Assess patient-specific factors for level of risk of tumor lysis syndrome (TLS) and provide prophylactic hydration and anti-hyperuricemics to patients prior to first dose of VENCLEXTA to reduce risk of TLS [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. Administer the VENCLEXTA dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg as shown in Table 1. The 5-week ramp-up dosing schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of TLS. Instruct patients to take VENCLEXTA tablets with a meal and water at approximately the same time each day. VENCLEXTA tablets should be swallowed whole and not chewed, crushed, or broken prior to swallowing. Table 1. Dosing Schedule for Ramp-Up Phase Week VENCLEXTA Daily Dose 1 20 mg 2 50 mg 3 100 mg 4 200 mg 5 and beyond 400 mg The Starting Pack provides the first 4 weeks of VENCLEXTA according to the ramp-up schedule. Once the ramp-up phase is completed, the 400 mg dose is achieved using 100 mg tablets supplied in bottles [see How Supplied/Storage and Handling (16)]. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed. 2.3 Risk Assessment and Prophylaxis for Tumor Lysis Syndrome VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS in the initial 5-week ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase. The risk of TLS is a continuum based on multiple factors, including tumor burden and comorbidities. Perform tumor burden assessments, including radiographic evaluation (e.g., CT scan), assess blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) in all patients and correct pre-existing abnormalities prior to initiation of treatment with VENCLEXTA. Reduced renal function (creatinine clearance [CrCl] <80 mL/min) further increases the risk. The risk may decrease as tumor burden decreases [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)]. Table 2 below describes the recommended TLS prophylaxis and monitoring during VENCLEXTA treatment based on tumor burden determination from clinical trial data. Table 2. Recommended TLS Prophylaxis Based on Tumor Burden From Clinical Trial Data (consider all patient co-morbidities before final determination of prophylaxis and monitoring schedule) Tumor Burden Prophylaxis Blood Chemistry Monitoringc,d   Hydrationa Anti-hyperuricemics Setting and Frequency of Assessments Low All LN <5 cm AND ALC <25 x109/L Oral (1.5-2 L) Allopurinolb Outpatient Pre-dose, 6 to 8 hours, 24 hours at first dose of 20 mg and 50 mg Pre-dose at subsequent ramp-up doses Medium Any LN 5 cm to <10 cm OR ALC ≥25 x109/L Oral (1.5-2 L) and consider additional intravenous Allopurinol Outpatient Pre-dose, 6 to 8 hours, 24 hours at first dose of 20 mg and 50 mg Pre-dose at subsequent ramp-up doses Consider hospitalization for patients with CrCl <80ml/min at first dose of 20 mg and 50 mg; see below for monitoring in hospital High Any LN ≥10 cm OR ALC ≥25 x109/L AND any LN ≥5 cm Oral (1.5-2L) and intravenous (150-200 mL/hr as tolerated) Allopurinol; consider rasburicase if baseline uric acid is elevated In hospital at first dose of 20 mg and 50 mg Pre-dose, 4, 8,12 and 24 hours Outpatient at subsequent ramp-up doses Pre-dose, 6 to 8 hours, 24 hours ALC = absolute lymphocyte count; LN = lymph node. aAdminister intravenous hydration for any patient who cannot tolerate oral hydration. bStart allopurinol or xanthine oxidase inhibitor 2 to 3 days prior to initiation of VENCLEXTA. cEvaluate blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine); review in real time. dFor patients at risk of TLS, monitor blood chemistries at 6 to 8 hours and at 24 hours at each subsequent ramp-up dose. 2.4 Dose Modifications Based on Toxicities Interrupt dosing or reduce dose for toxicities. See Table 3 for dose modifications for hematologic and other toxicities related to VENCLEXTA, and Table 4 for dose. For patients who have had a dosing interruption greater than 1 week during the first 5 weeks of ramp-up phase or greater than 2 weeks when at the daily dose of 400 mg, reassess for risk of TLS to determine if reinitiation with a reduced dose is necessary (e.g., all or some levels of the dose ramp-up schedule) [see Dosage and Administration (2.2, 2.3)]. Table 3. Recommended Dose Modifications for Toxicitiesa Event Occurrence Action Tumor Lysis Syndrome Blood chemistry changes or symptoms suggestive of TLS Any Withhold the next day’s dose. If resolved within 24 to 48 hours of last dose, resume at the same dose. For any blood chemistry changes requiring more than 48 hours to resolve, resume at a reduced dose (see Table 4) [see Dosage and Administration (2.3)]. For any events of clinical TLS,b resume at a reduced dose following resolution (see Table 4) [see Dosage and Administration (2.3)]. Non-Hematologic Toxicities Grade 3 or 4 non-hematologic toxicities 1st occurrence Interrupt VENCLEXTA. Once the toxicity has resolved to Grade 1 or baseline level, VENCLEXTA therapy may be resumed at the same dose. No dose modification is required. 2nd and subsequent occurrences Interrupt VENCLEXTA. Follow dose reduction guidelines in Table 4 when resuming treatment with VENCLEXTA after resolution. A larger dose reduction may occur at the discretion of the physician. Hematologic Toxicities Grade 3 or 4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except lymphopenia) [see Warnings and Precautions (5.2)] 1st occurrence Interrupt VENCLEXTA. To reduce the infection risks associated with neutropenia, granulocyte-colony stimulating factor (G-CSF) may be administered with VENCLEXTA if clinically indicated. Once the toxicity has resolved to Grade 1 or baseline level, VENCLEXTA therapy may be resumed at the same dose. 2nd and subsequent occurrences Interrupt VENCLEXTA. Consider using G-CSF as clinically indicated. Follow dose reduction guidelines in Table 4 when resuming treatment with VENCLEXTA after resolution. A larger dose reduction may occur at the discretion of the physician. Consider discontinuing VENCLEXTA for patients who require dose reductions to less than 100 mg for more than 2 weeks. aAdverse reactions were graded using NCI CTCAE version 4.0. bClinical TLS was defined as laboratory TLS with clinical consequences such as acute renal failure, cardiac arrhythmias, or sudden death and/or seizures. Table 4. Dose Modification for Toxicity During VENCLEXTA Treatment Dose at Interruption, mg Restart Dose, mga 400 300 300 200 200 100 100 50 50 20 20 10 aDuring the ramp-up phase, continue the reduced dose for 1 week before increasing the dose.  2.5 Dose Modifications for Use with CYP3A and P-gp Inhibitors Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated. Concomitant use of VENCLEXTA with strong CYP3A inhibitors increases venetoclax exposure (i.e., Cmax and AUC) and may increase the risk for TLS at initiation and during ramp-up phase [see Contraindications (4)]. For patients who have completed the ramp-up phase and are on a steady daily dose of VENCLEXTA, reduce the VENCLEXTA dose by at least 75% when strong CYP3A inhibitors must be used concomitantly. Avoid concomitant use of VENCLEXTA with moderate CYP3A inhibitors or P-gp inhibitors. Consider alternative treatments. If a moderate CYP3A inhibitor or a P-gp inhibitor must be used, reduce the VENCLEXTA dose by at least 50%. Monitor these patients more closely for signs of toxicities [see Dosage and Administration (2.4)]. Resume the VENCLEXTA dose that was used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor [see Dosage and Administration (2.4) and Drug Interactions (7.1)]. The recommendations for managing drug-drug interactions are summarized in Table 5. Table 5. Management of Potential VENCLEXTA Interactions with CYP3A and P-gp Inhibitors  Inhibitors Initiation and Ramp-Up Phase Steady Daily Dose (After Ramp-Up Phase) Strong CYP3A inhibitor Contraindicated Avoid inhibitor use or reduce the VENCLEXTA dose by at least 75% Moderate CYP3A inhibitor Avoid inhibitor use or reduce the VENCLEXTA dose by at least 50% P-gp inhibitor 2.6 Missed Dose If the patient misses a dose of VENCLEXTA within 8 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal daily dosing schedule. If a patient misses a dose by more than 8 hours, the patient should not take the missed dose and should resume the usual dosing schedule the next day. If the patient vomits following dosing, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time. 3 DOSAGE FORMS AND STRENGTHS Table 6. VENCLEXTA Tablet Strength and Description Tablet Strength Description of Tablet 10 mg Round, biconvex shaped, pale yellow film-coated tablet debossed with “V” on one side and “10” on the other side 50 mg Oblong, biconvex shaped, beige film-coated tablet debossed with “V” on one side and “50” on the other side 100 mg Oblong, biconvex shaped, pale yellow film-coated tablet debossed with “V” on one side and “100” on the other side 4 CONTRAINDICATIONS Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated [see Dosage and Administration (2.5) and Drug Interactions (7.1)]. 5 WARNINGS AND PRECAUTIONS 5.1 Tumor Lysis Syndrome Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in previously treated CLL patients with high tumor burden when treated with VENCLEXTA [see Adverse Reactions (6.1)]. VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS in the initial 5-week ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase. The risk of TLS is a continuum based on multiple factors, including tumor burden (see Table 2) and comorbidities. Reduced renal function (CrCl <80 mL/min) further increases the risk. Patients should be assessed for risk and should receive appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed. Employ more intensive measures (intravenous hydration, frequent monitoring, hospitalization) as overall risk increases [see Dosage and Administration (2.3, 2.4) and Use in Specific Populations (8.6)]. Concomitant use of VENCLEXTA with strong or moderate CYP3A inhibitors and P-gp inhibitors increases venetoclax exposure, may increase the risk of TLS at initiation and during ramp-up phase and may require VENCLEXTA dose adjustment [see Dosage and Administration (2.5) and Drug Interactions (7.1)]. 5.2 Neutropenia Grade 3 or 4 neutropenia occurred in 41% (98/240) of patients treated with VENCLEXTA [see Adverse Reactions (6.1)]. Monitor complete blood counts throughout the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF) [see Dosage and Administration (2.4)]. 5.3 Immunization Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. The safety and efficacy of immunization with live attenuated vaccines during or following VENCLEXTA therapy have not been studied. Advise patients that vaccinations may be less effective. 5.4 Embryo-Fetal Toxicity Based on its mechanism of action and findings in animals, VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. In an embryo-fetal study conducted in mice, administration of venetoclax to pregnant animals at exposures equivalent to that observed in patients at the recommended dose of 400 mg daily resulted in post-implantation loss and decreased fetal weight. There are no adequate and well-controlled studies in pregnant woman using VENCLEXTA. Advise females of reproductive potential to avoid pregnancy during treatment. If VENCLEXTA is used during pregnancy or if the patient becomes pregnant while taking VENCLEXTA, the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)]. 6 ADVERSE REACTIONS The following serious adverse events are discussed in greater detail in other sections of the labeling: Tumor Lysis Syndrome [see Warnings and Precautions (5.1)] Neutropenia [see Warnings and Precautions (5.2)] Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice. 6.1 Clinical Trial Experience The safety of single agent VENCLEXTA at the 400 mg recommended daily dose following a dose ramp-up schedule is based on pooled data of 240 patients with previously treated CLL from two phase 2 trials and one phase 1 trial. In the pooled dataset, the median age was 66 years (range: 29 to 85 years), 95% were white, and 69% were male. The median number of prior therapies was 3 (range: 1 to 12). The median duration of treatment with VENCLEXTA at the time of data analysis was approximately 10.3 months (range: 0 to 34.1 months). Approximately 46% of patients received VENCLEXTA for more than 48 weeks. The most common adverse reactions (≥20%) of any grade were neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were reported in 43.8% of patients. The most frequent serious adverse reactions (≥2%) were pneumonia, febrile neutropenia, pyrexia, autoimmune hemolytic anemia (AIHA), anemia, and TLS. Discontinuations due to adverse reactions occurred in 8.3% of patients. The most frequent adverse reactions leading to drug discontinuation were thrombocytopenia and AIHA. Dosage adjustments due to adverse reactions occurred in 9.6% of patients. The most frequent adverse reactions leading to dose adjustments were neutropenia, febrile neutropenia, and thrombocytopenia. Adverse reactions reported in 3 trials of patients with previously treated CLL using single agent VENCLEXTA are presented in Table 7. Table 7. Adverse Reactions Reported in ≥10% (Any Grade) or ≥5% (Grade 3 or 4) of Patients with CLL Body System Adverse Reaction Any Grade (%) N=240 Grade 3 or 4 (%) N=240 Blood and lymphatic system disorders Neutropeniaa 45 41 Anemiab 29 18 Thrombocytopeniac 22 15 Febrile neutropenia 5 5 Gastrointestinal disorders Diarrhea 35 <1 Nausea 33 <1 Vomiting 15 <1 Constipation 14 0 General disorders and administration site conditions Fatigue 21 2 Pyrexia 16 <1 Peripheral edema 11 <1 Infections and infestations Upper respiratory tract infection 22 1 Pneumonia 8 5 Metabolic and nutrition disorders Hypokalemia 12 4 Musculoskeletal and connective tissue disorders Back pain 10 <1 Nervous system disorders Headache 15 <1 Respiratory, thoracic, and mediastinal disorders Cough 13 0 Adverse Reactions graded using NCI Common Terminology Criteria for Adverse Events version 4.0. aNeutropenia/neutrophil count decreased. bAnemia/hemoglobin decreased. cThrombocytopenia/platelet count decreased. Tumor Lysis Syndrome Tumor lysis syndrome is an important identified risk when initiating VENCLEXTA. In the initial Phase 1 dose-finding trials, which had shorter (2-3 week) ramp-up phase and higher starting dose, the incidence of TLS was 12% (9/77; 4 laboratory TLS, 5 clinical TLS), including 2 fatal events and 3 events of acute renal failure, 1 requiring dialysis. The risk of TLS was reduced after revision of the dosing regimen and modification to prophylaxis and monitoring measures [see Dosage and Administration (2.2, 2.3)]. In venetoclax clinical trials, patients with any measurable lymph node ≥10 cm or those with both an ALC ≥25 x 109/L and any measurable lymph node ≥5 cm were hospitalized to enable more intensive hydration and monitoring for the first day of dosing at 20 mg and 50 mg during the ramp-up phase. In 66 patients with CLL starting with a daily dose of 20 mg and increasing over 5 weeks to a daily dose of 400 mg, the rate of TLS was 6%. All events either met laboratory TLS criteria (laboratory abnormalities that met ≥2 of the following within 24 hours of each other: potassium >6 mmol/L, uric acid >476 µmol/L, calcium <1.75 mmol/L, or phosphorus >1.5 mmol/L); or were reported as TLS events. The events occurred in patients who had a lymph node(s) ≥5 cm or ALC ≥25 x 109/L. No TLS with clinical consequences such as acute renal failure, cardiac arrhythmias or sudden death and/or seizures was observed in these patients. All patients had CrCl ≥50 mL/min. Laboratory abnormalities relevant to TLS observed in 66 patients with CLL who followed the dose ramp-up schedule and TLS prophylaxis measures are presented in Table 8. Table 8. Adverse Reactions of TLS and Relevant Laboratory Abnormalities Reported in Patients with CLL Parameter All Grades (%) N=66 Grade ≥3 (%) N=66 Laboratory TLSa 6 6 Hyperkalemiab 20 2 Hyperphosphatemiac 15 3 Hypocalcemiad 9 3 Hyperuricemiae 6 2 aLaboratory abnormalities that met ≥2 of the following criteria within 24 hours of each other: potassium >6 mmol/L, uric acid >476 µmol/L, calcium <1.75 mmol/L, or phosphorus >1.5 mmol/L; or were reported as TLS events. bHyperkalemia/blood potassium increased. cHyperphosphatemia/blood phosphorus increased. dHypocalcemia/blood calcium decreased. eHyperuricemia/blood uric acid increased.  Close 7 DRUG INTERACTIONS 7.1 Effects of Other Drugs on VENCLEXTA Venetoclax is predominantly metabolized by CYP3A4/5. Strong CYP3A Inhibitors Concomitant use of VENCLEXTA with strong CYP3A inhibitors (e.g., ketoconazole, conivaptan, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, telaprevir, posaconazole and voriconazole) at initiation and during ramp-up phase is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3)]. For patients who have completed the ramp-up phase and are on a steady daily dose of VENCLEXTA, reduce the VENCLEXTA dose by at least 75% when used concomitantly with strong CYP3A inhibitors. Resume the VENCLEXTA dose that was used prior to initiating the CYP3A inhibitor 2 to 3 days after discontinuation of the inhibitor [see Dosage and Administration (2.4, 2.5) and Clinical Pharmacology (12.3)]. Co-administration of ketoconazole increased venetoclax Cmax by 2.3-fold and AUC∞ by 6.4-fold. Moderate CYP3A Inhibitors and P-gp Inhibitors Avoid concomitant use of moderate CYP3A inhibitors (e.g., erythromycin, ciprofloxacin, diltiazem, dronedarone, fluconazole, verapamil) or P-gp inhibitors (e.g., amiodarone, azithromycin, captopril, carvedilol, cyclosporine, felodipine, quercetin, quinidine, ranolazine, ticagrelor) with VENCLEXTA. Consider alternative treatments. If a moderate CYP3A inhibitor or a P-gp inhibitor must be used, reduce the VENCLEXTA dose by at least 50%. Monitor patients more closely for signs of VENCLEXTA toxicities [see Dosage and Administration (2.4, 2.5) and Clinical Pharmacology (12.3)]. Resume the VENCLEXTA dose that was used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. Avoid grapefruit products, Seville oranges, and starfruit during treatment with VENCLEXTA, as they contain inhibitors of CYP3A. Co-administration of a single dose of rifampin, a P-gp inhibitor, increased venetoclax Cmax by 106% and AUC∞ by 78%. CYP3A Inducers Avoid concomitant use of VENCLEXTA with strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin). Consider alternative treatments with less CYP3A induction [see Clinical Pharmacology (12.3)]. Co-administration of multiple doses of rifampin, a strong CYP3A inducer, decreased venetoclax Cmax by 42% and AUC∞ by 71%. 7.2 Effects of VENCLEXTA on Other Drugs Warfarin In a drug-drug interaction study in healthy subjects, administration of a single dose of venetoclax with warfarin resulted in an 18% to 28% increase in Cmax and AUC∞ of R-warfarin and S-warfarin. Because venetoclax was not dosed to steady state, it is recommended that the international normalized ratio (INR) be monitored closely in patients receiving warfarin. P-gp substrates In vitro data suggest venetoclax has inhibition potential on P-gp substrates at therapeutic dose levels in the gut. Therefore, co-administration of narrow therapeutic index P-gp substrates (e.g., digoxin, everolimus, and sirolimus) with VENCLEXTA should be avoided. If a narrow therapeutic index P-gp substrate must be used, it should be taken at least 6 hours before VENCLEXTA. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available human data on the use of VENCLEXTA in pregnant women. Based on toxicity observed in mice, VENCLEXTA may cause fetal harm when administered to pregnant women. In mice, venetoclax was fetotoxic at exposures 1.2 times the human clinical exposure based on AUC at the recommended human dose of 400 mg daily. If VENCLEXTA is used during pregnancy or if the patient becomes pregnant while taking VENCLEXTA, the patient should be apprised of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal data In embryo-fetal development studies, venetoclax was administered to pregnant mice and rabbits during the period of organogenesis. In mice, venetoclax was associated with increased post-implantation loss and decreased fetal body weight at 150 mg/kg/day (maternal exposures approximately 1.2 times the human AUC exposure at the recommended dose of 400 mg daily). No teratogenicity was observed in either the mouse or the rabbit. 8.2 Lactation Risk Summary There are no data on the presence of VENCLEXTA in human milk, the effects of VENCLEXTA on the breastfed child, or the effects of VENCLEXTA on milk production. Because many drugs are excreted in human milk and because the potential for serious adverse reactions in breastfed infants from VENCLEXTA is unknown, advise nursing women to discontinue breastfeeding during treatment with VENCLEXTA. 8.3 Females and Males of Reproductive Potential VENCLEXTA may cause fetal harm [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)]. Pregnancy Testing Females of reproductive potential should undergo pregnancy testing before initiation of VENCLEXTA [see Use in Specific Populations (8.1)]. Contraception Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose [see Use in Specific Populations (8.1)]. Infertility Based on findings in animals, male fertility may be compromised by treatment with VENCLEXTA [see Nonclinical Toxicology (13.1)]. 8.4 Pediatric Use Safety and effectiveness have not been established in pediatric patients. 8.5 Geriatric Use Of the 106 patients with previously treated CLL with 17p deletion who were evaluated for efficacy, 57% were ≥65 years of age and 17% were ≥75 years of age. Of the 240 patients with previously treated CLL evaluated for safety from 3 open-label trials, 58% were ≥65 years of age and 17% were ≥75 years of age. No overall differences in safety and effectiveness were observed between older and younger patients. 8.6 Renal Impairment Patients with reduced renal function (CrCl <80 mL/min) are at increased risk of TLS. These patients may require more intensive prophylaxis and monitoring to reduce the risk of TLS when initiating treatment with VENCLEXTA [see Dosage and Administration (2.3, 2.4)]. No specific clinical trials have been conducted in subjects with renal impairment. Less than 0.1% of radioactive VENCLEXTA dose was detected in urine. No dose adjustment is needed for patients with mild or moderate renal impairment (CrCl ≥30 mL/min) based on results of the population pharmacokinetic analysis [see Clinical Pharmacology (12.3)]. A recommended dose has not been determined for patients with severe renal impairment (CrCl <30 mL/min) or patients on dialysis. 8.7 Hepatic Impairment No specific clinical trials have been conducted in subjects with hepatic impairment, however human mass balance study showed that venetoclax undergoes hepatic elimination. Although no dose adjustment is recommended in patients with mild or moderate hepatic impairment based on results of the population pharmacokinetic analysis [see Clinical Pharmacology (12.3)], a trend for increased adverse events was observed in patients with moderate hepatic impairment; monitor these patients more closely for signs of toxicity during the initiation and dose ramp-up phase. A recommended dose has not been determined for patients with severe hepatic impairment. 10 OVERDOSAGE There is no specific antidote for VENCLEXTA. For patients who experience overdose, closely monitor and provide appropriate supportive treatment; during ramp-up phase interrupt VENCLEXTA and monitor carefully for signs and symptoms of TLS along with other toxicities [see Dosage and Administration (2.3, 2.4)]. Based on venetoclax large volume of distribution and extensive protein binding, dialysis is unlikely to result in significant removal of venetoclax. 11 DESCRIPTION Venetoclax is a selective inhibitor of BCL-2 protein. It is a light yellow to dark yellow solid with the empirical formula C45H50ClN7O7S and a molecular weight of 868.44. Venetoclax has very low aqueous solubility. Venetoclax is described chemically as 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) and has the following chemical structure: VENCLEXTA tablets for oral administration are supplied as pale yellow or beige tablets that contain 10, 50, or 100 mg venetoclax as the active ingredient. Each tablet also contains the following inactive ingredients: copovidone, colloidal silicon dioxide, polysorbate 80, sodium stearyl fumarate, and calcium phosphate dibasic. In addition, the 10 mg and 100 mg coated tablets include the following: iron oxide yellow, polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide. The 50 mg coated tablets also include the following: iron oxide yellow, iron oxide red, iron oxide black, polyvinyl alcohol, talc, polyethylene glycol and titanium dioxide. Each tablet is debossed with “V” on one side and “10”, “50” or “100” corresponding to the tablet strength on the other side. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of multiple doses of VENCLEXTA up to 1200 mg once daily on the QTc interval was evaluated in an open-label, single-arm study in 176 patients with previously treated hematologic malignancies. VENCLEXTA had no large effect on QTc interval (i.e., > 20 ms) and there was no relationship between venetoclax exposure and change in QTc interval. 12.3 Pharmacokinetics Absorption Following multiple oral administrations under fed conditions, maximum plasma concentration of venetoclax was reached 5-8 hours after dose. Venetoclax steady state AUC increased proportionally over the dose range of 150-800 mg. Under low-fat meal conditions, venetoclax mean (± standard deviation) steady state Cmax was 2.1 ± 1.1 μg/mL and AUC0-24 was32.8 ± 16.9 μg•h/mL at the 400 mg once daily dose. Food Effect Administration with a low-fat meal increased venetoclax exposure by approximately 3.4-fold and administration with a high-fat meal increased venetoclax exposure by 5.1- to 5.3-fold compared to fasting conditions. Venetoclax should be administered with a meal [see Dosage and Administration (2.2)]. Distribution Venetoclax is highly bound to human plasma protein with unbound fraction in plasma <0.01 across a concentration range of 1-30 µM (0.87-26 µg/mL). The mean blood-to-plasma ratio was 0.57. The population estimate for apparent volume of distribution (Vdss/F) of venetoclax ranged from 256-321 L in patients. Elimination The population estimate for the terminal elimination half-life of venetoclax was approximately 26 hours. The pharmacokinetics of venetoclax does not change over time. Metabolism In vitro studies demonstrated that venetoclax is predominantly metabolized by CYP3A4/5. M27 was identified as a major metabolite in plasma with an inhibitory activity against BCL-2 that is at least 58-fold lower than venetoclax in vitro. Excretion After single oral administration of 200 mg radiolabeled [14C]-venetoclax dose to healthy subjects, >99.9% of the dose was recovered in feces and <0.1% of the dose was excreted in urine within 9 days, indicating that hepatic elimination is responsible for the clearance of venetoclax from the systemic circulation. Unchanged venetoclax accounted for 20.8% of the administered radioactive dose excreted in feces. Special Populations Age, Race, Sex, and Weight Based on population pharmacokinetic analyses, age, race, sex, and weight do not have a clinically meaningful effect on venetoclax clearance. Renal Impairment Based on a population pharmacokinetic analysis that included 211 subjects with mild renal impairment (CrCl ≥60 and <90 mL/min, calculated by Cockcroft-Gault equation), 83 subjects with moderate renal impairment (CrCl ≥30 and <60 mL/min) and 210 subjects with normal renal function (CrCl ≥90 mL/min), venetoclax exposures in subjects with mild or moderate renal impairment are similar to those with normal renal function. The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment (CrCl <30 mL/min) or subjects on dialysis [see Use in Specific Populations (8.6)]. Hepatic Impairment Based on a population pharmacokinetic analysis that included 69 subjects with mild hepatic impairment, 7 subjects with moderate hepatic impairment and 429 subjects with normal hepatic function, venetoclax exposures are similar in subjects with mild and moderate hepatic impairment and normal hepatic function. The NCI Organ Dysfunction Working Group criteria for hepatic impairment were used in the analysis. Mild hepatic impairment was defined as normal total bilirubin and aspartate transaminase (AST) > upper limit of normal (ULN) or total bilirubin >1.0 to 1.5 times ULN, moderate hepatic impairment as total bilirubin >1.5 to 3.0 times ULN, and severe hepatic impairment as total bilirubin >3.0 times ULN. The pharmacokinetics of venetoclax has not been studied in subjects with severe hepatic impairment [see Use in Specific Populations (8.7)]. Drug Interactions Ketoconazole Co-administration of 400 mg once daily ketoconazole, a strong CYP3A, P-gp and BCRP inhibitor, for 7 days in 11 previously treated NHL patients increased venetoclax Cmax by 2.3-fold and AUC∞ by 6.4-fold [see Drug Interactions (7.1)]. Rifampin multiple doses Co-administration of 600 mg once daily rifampin, a strong CYP3A inducer, for 13 days in 10 healthy subjects decreased venetoclax Cmax by 42% and AUC∞ by 71% [see Drug Interactions (7.1)]. Rifampin single dose Co-administration of a 600 mg single dose of rifampin, an OATP1B1/1B3 and P-gp inhibitor, in 11 healthy subjects increased venetoclax Cmax by 106% and AUC∞ by 78% [see Drug Interactions (7.1)]. Gastric Acid Reducing Agents Based on population pharmacokinetic analysis, gastric acid reducing agents (e.g., proton pump inhibitors, H2-receptor antagonists, antacids) do not affect venetoclax bioavailability. Warfarin In a drug-drug interaction study in three healthy subjects, administration of a single 400 mg dose of venetoclax with 5 mg warfarin resulted in 18% to 28% increase in Cmax and AUC∞ of R-warfarin and S-warfarin [see Drug Interactions (7.2)]. In vitro Studies In vitro studies indicated that venetoclax is not an inhibitor or inducer of CYP1A2, CYP2B6, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. Venetoclax is a weak inhibitor of CYP2C8, CYP2C9, and UGT1A1 in vitro, but it is not predicted to cause clinically relevant inhibition due to high plasma protein binding. Venetoclax is not an inhibitor of UGT1A4, UGT1A6, UGT1A9, or UGT2B7. Venetoclax is a P-gp and BCRP substrate as well as a P-gp and BCRP inhibitor and weak OATP1B1 inhibitor in vitro. To avoid a potential interaction in the gastrointestinal tract, co-administration of narrow therapeutic index P-gp substrates such as digoxin with VENCLEXTA should be avoided. If a narrow therapeutic index P-gp substrate must be used, it should be taken at least 6 hours before VENCLEXTA. Venetoclax is not expected to inhibit OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, or MATE2K at clinically relevant concentrations. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with venetoclax. Venetoclax was not mutagenic in an in vitro bacterial mutagenicity (Ames) assay, did not induce numerical or structural aberrations in an in vitro chromosome aberration assay using human peripheral blood lymphocytes, and was not clastogenic in an in vivo mouse bone marrow micronucleus assay at doses up to 835 mg/kg. The M27 metabolite was negative for genotoxic activity in in vitro Ames and chromosome aberration assays. Fertility and early embryonic development studies were conducted in male and female mice. These studies evaluate mating, fertilization, and embryonic development through implantation. There were no effects of venetoclax on estrus cycles, mating, fertility, corpora lutea, uterine implants or live embryos per litter at dosages up to 600 mg/kg/day. However, a risk to human male fertility exists based on testicular toxicity (germ cell loss) observed in dogs at exposures as low as 0.5 times the human AUC exposure at the recommend dose. 13.2 Animal Toxicology and/or Pharmacology In dogs, venetoclax caused single-cell necrosis in various tissues, including the gallbladder, exocrine pancreas, and stomach with no evidence of disruption of tissue integrity or organ dysfunction; these findings were minimal to mild in magnitude. Following a 4-week dosing period and subsequent 4-week recovery period, minimal single-cell necrosis was still present in some tissues and reversibility has not been assessed following longer periods of dosing or recovery. In addition, after approximately 3 months of daily dosing in dogs, venetoclax caused progressive white discoloration of the hair coat, due to loss of melanin pigment. 14 CLINICAL STUDIES The efficacy of VENCLEXTA was established in an open-label, single-arm, multicenter clinical trial of 106 patients with CLL with 17p deletion who had received at least one prior therapy. In the study, 17p deletion was confirmed in peripheral blood specimens from patients using Vysis CLL FISH Probe Kit, which is FDA approved for selection of patients for VENCLEXTA treatment. Patients received VENCLEXTA via a weekly ramp-up schedule starting at 20 mg and ramping to 50 mg, 100 mg, 200 mg and finally 400 mg once daily. Patients continued to receive 400 mg of VENCLEXTA orally once daily until disease progression or unacceptable toxicity. The efficacy of VENCLEXTA was evaluated by overall response rate (ORR) as assessed by an Independent Review Committee (IRC) using the International Workshop for Chronic Lymphocytic Leukemia (IWCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008). Table 9 summarizes the baseline demographic and disease characteristics of the study population. Table 9. Baseline Patient Characteristics  Characteristics N = 106 Age, years; median (range) 67 (37-83) White; % 97.1 Male; % 65.1 ECOG performance status; %      0      1      2 39.6 51.9 8.5 Tumor burden; %      Absolute lymphocyte count ≥25 x 109/L      One or more nodes ≥5 cm 50.0 52.8 Number of prior therapies; median (range) 2.5 (1-10) Time since diagnosis, months; median (range)a 79.4 (1.2-385.6) aN=105. The median time on treatment at the time of evaluation was 12.1 months (range: 0 to 21.5 months). Efficacy results are shown in Table 10. Table 10. Efficacy Results for Patients with Previously Treated CLL with 17p Deletion by IRC  VENCLEXTA N=106 ORR, n (%)      (95% CI) 85 (80.2) (71.3, 87.3)      CR + CRi, n (%)        CR, n (%)        CRi, n (%) 8 (7.5) 6 (5.7) 2 (1.9)      nPR, n (%) 3 (2.8)      PR, n (%) 74 (69.8) CI = confidence interval; CR = complete remission; CRi = complete remission with incomplete marrow recovery; IRC = independent review committee; nPR = nodular partial remission; ORR = overall response rate (CR + CRi + nPR + PR); PR = partial remission. The median time to first response was 0.8 months (range: 0.1 to 8.1 months). Median duration of response (DOR) has not been reached with approximately 12 months median follow-up. The DOR ranged from 2.9 to 19.0+ months. Minimal residual disease (MRD) was evaluated in peripheral blood and bone marrow for patients who achieved CR or CRi, following treatment with VENCLEXTA. Three percent (3/106) were MRD negative in the peripheral blood and bone marrow (less than one CLL cell per 104 leukocytes). 16 HOW SUPPLIED/STORAGE AND HANDLING VENCLEXTA is dispensed as follows: Packaging Presentation Number of Tablets National Drug Code (NDC)  Starting Pack  Each pack contains four weekly wallet blister packs: Week 1 (14 x 10 mg tablets) Week 2 (7 x 50 mg tablets) Week 3 (7 x 100 mg tablets) Week 4 (14 x 100 mg tablets)  0074-0579-28  10 mg Wallet  14 x 10 mg tablets  0074-0561-14  50 mg Wallet  7 x 50 mg tablets  0074-0566-07  10 mg Unit Dose  2 x 10 mg tablets  0074-0561-11  50 mg Unit Dose  1 x 50 mg tablet  0074-0566-11  100 mg Unit Dose  1 x 100 mg tablet  0074-0576-11  100 mg Bottle  120 x 100 mg tablets  0074-0576-22 VENCLEXTA 10 mg film-coated tablets are round, biconvex shaped, pale yellow debossed with “V” on one side and “10” on the other side. VENCLEXTA 50 mg film-coated tablets are oblong, biconvex shaped, beige debossed with “V” on one side and “50” on the other side. VENCLEXTA 100 mg film-coated tablets are oblong, biconvex shaped, pale yellow debossed with “V” on one side and “100” on the other side. Store at or below 86°F (30°C). 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Tumor Lysis Syndrome Advise patients of the potential risk of TLS, particularly at treatment initiation and during ramp-up phase, and to immediately report any signs and symptoms associated with this event (fever, chills, nausea, vomiting, confusion, shortness of breath, seizure, irregular heartbeat, dark or cloudy urine, unusual tiredness, muscle pain, and/or joint discomfort) to their doctor for evaluation [see Warnings and Precautions (5.1)]. Advise patients to be adequately hydrated every day when taking VENCLEXTA to reduce the risk of TLS. The recommended volume is 6 to 8 glasses (approximately 56 ounces total) of water each day. Patients should drink water starting 2 days before and on the day of the first dose, and every time the dose is increased [see Dosage and Administration (2.3)]. Advise patients of the importance of keeping scheduled appointments for blood work or other laboratory tests [see Dosage and Administration (2.3)]. Advise patients that it may be necessary to take VENCLEXTA in the presence of a doctor to allow monitoring for TLS. Neutropenia Advise patients to contact their doctor immediately if they develop a fever or any signs of infection. Advise patients of the need for periodic monitoring of blood counts [see Warnings and Precautions (5.2)]. Drug Interactions Advise patients to avoid consuming grapefruit products, Seville oranges, or starfruit during treatment with VENCLEXTA. Advise patients that VENCLEXTA may interact with some drugs; therefore, advise patients to inform their doctor of the use of any prescription medication, over-the-counter drugs, vitamins and herbal products [see Contraindications (4) and Drug Interactions (7.1)]. Immunizations Advise patients to avoid vaccination with live vaccines because they may not be safe or effective during treatment with VENCLEXTA [see Warnings and Precautions (5.3)]. Pregnancy and Lactation Advise women of the potential risk to the fetus and to avoid pregnancy during treatment with VENCLEXTA. Advise female patients of reproductive potential to use effective contraception during therapy and for at least 30 days after completing of therapy. Advise females to contact their doctor if they become pregnant, or if pregnancy is suspected, during treatment with VENCLEXTA. Also advise patients not to breastfeed while taking VENCLEXTA [see Warnings and Precautions (5.4), and Use in Specific Populations (8.1, 8.2, and 8.3)]. Male Infertility Advise patients of the possibility of infertility and possible use of sperm banking for males of reproductive potential [see Use in Specific Populations (8.3)]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018 2016年4月11日，美国食品和药物管理局批准venetoclax（VENCLEXTA片，由艾伯维公司和基因泰克美国公司销售）用于治疗慢性淋巴细胞白血病（CLL）与17p缺失的治疗，如经检测FDA批准的试验，谁收到至少一个以前的治疗。 批准是基于一个阶段2，对于CLL患者窝藏谁收到至少一个前治疗17p缺失治疗venetoclax的单臂试验的结果。由独立的审查委员会（IRC）作为评估的主要疗效终点指标是根据肿瘤反应，2008年修改的IWCLL NCI-WG准则总反应率（ORR）。响应（DOR）的持续时间是一个额外的测量结果。 该试验入选谁收到与17p缺失至少一个以前的治疗，原位杂交（FISH）探头套件FDA批准的CLL荧光检测为106例。患者有2.​​5前处理（范围1-10）的中位数。该ORR通过IRC为80％（95％CI：71％，87％），8％，完全缓解（包括骨髓不完全恢复2％的完全缓解）。微小残留病（MRD）外周血和骨髓进行了评估谁取得CR或CRI，在与venetoclax治疗的患者。患者在意向治疗人群百分之三达到完全缓解（CR或CRI）和也是阴性的MRD在骨髓和外周血。中位时间为第一个反应是0.8个月（范围：0.1至8.1个月）。响应（DOR）的中位时间还没有达到与大约12个月平均随访。该DOR从2.9不等超过19.0个月。 在240例患者的安全性数据进行评估与谁用单药venetoclax在400毫克目标剂量口服，每日处理以前处理过的CLL。任何等级的最常见的（大于或等于20％）的不良反应为中性粒细胞减少，腹泻，恶心，贫血，上呼吸道感染，血小板减少症，和疲劳。严重的不良反应的报道在44％的患者，和最常见的（大于或等于2％）严重不良反应是肺炎，发热性中性粒细胞减少，发热，自身免疫性溶血性贫血，贫血，肿瘤溶解综合征（TLS）。 由于在肿瘤体积的迅速减少，TLS是发起venetoclax时一个重要的识别的风险。 TLS的风险降低与肿瘤负担分层，预防与电解质异常的水化和抗hyperuricemics，频繁血液化学监测和纠正。患者的高风险特征，可能需要住院四水合，电解质监控和电解质异常的侵略性的校正。在66 CLL患者开始每日剂量为20毫克和为5周增加至每日剂量为400毫克，TLS率为6％，无临床事件。所有事件是实验室TLS和患者发生谁了淋巴结（多个）大于或等于5厘米的ALC大于或等于25×109/L。 为venetoclax经批准的指示的推荐剂量和时间表是在5周斜坡上升时间表。给药在20毫克1周，随后1周的50毫克，100毫克和200毫克，然后400毫克直至疾病进展或不能接受的毒性的推荐剂量为每日每剂量水平开始。 此应用程序是6月29日的处方药使用者费用法案（PDUFA）目标日期前得到批准，2016年Venetoclax获得罕见病药物地位治疗CLL并获得突破性疗法命名为17p缺失CLL发展计划。该应用程序被授予优先审核，而目前的迹象是根据FDA的加速审批程序批准.